MétaCan
Menu
← Back to cohort

P134 The inflammatory bowel disease bioresource: focus on research facilitation

2021· article· en· W3200337234 on OpenAlexaboutno aff
Laetitia Pele, Rachel Simpkins, Catherine Thorbinson, Deepthy Francis, Rasha Shawky, Miles Parkes

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
Fundersnot available
KeywordsInflammatory bowel diseaseMedicineFamily medicineBiobankDiseaseClinical trialPhysical therapyInternal medicineBioinformatics

Abstract

fetched live from OpenAlex

Introduction The Inflammatory Bowel Disease (IBD) BioResource is a UK-wide platform comprising >32,000 Crohn’s and colitis patients across >100 participating hospitals with a long-standing goal of fostering IBD Research to expedite clinical translation. For each patient recruited, clinical and self-reported phenotype data are collected, alongside plasma, serum and DNA samples for genetic analyses. The resulting data-rich panel is open to any investigators wishing to access data/samples or recall genotype-selected participants to donate further samples or trial novel therapies. Methods Building the IBD BioResource panel: Patients’ clinical data are collected at recruitment by the IBD team through a clinical data sheet based on the Montreal classification while health and lifestyle information are obtained via a patient questionnaire. All include demographics, smoking habits, general and IBD specific health questions, family history of IBD and non-IBD conditions, medication, treatment, surgery history and co-morbidities. The IBD BioResource panel also holds Whole Genome/Exome sequencing and GWAS data derived from its detailed biological samplings. Accessing the IBD BioResource panel: The built-in panel of patients and their data is open to any investigators from science or industry. Following feasibility checks, submitted research applications are reviewed by the NIHR BioResource Scientific Advisory Board (SAB) based on scientific merits and projected benefit to patients. Upon study approval, patients meeting inclusion criteria are contacted by the NIHR BioResource team with a letter of invitation and a patient information leaflet. For volunteers willing to participate, appropriate arrangements are then made to gather information, collect fresh biological samples or engage patients in intervention studies. Results To date 26 ‘Stage 2 studies’ applied to utilise the IBD BioResource, 18 of which are currently active, 4 completed and 4 pending approval. Of the 26 applications, ~20% requested access to anonymised samples/data while the remaining ~80% required involvement of participants. Applications are national, with 7 from London, 6 from Cambridge, 4 from Oxford, 2 from Leeds. 2 from Pharma and 1 from Manchester, Exeter, Wolverhampton, Liverpool and Edinburgh. Field of studies include genetics, predictors and management of IBD; environmental, microbial and immunological contributors, fertility and well-being. Conclusion The IBD BioResource and its network are on course to facilitating IBD Research through access to their panel and furthering knowledge/understanding of IBD for the benefit of Crohn’s and colitis patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.048
metaresearch head score (Gemma)0.111
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.262
Threshold uncertainty score0.877

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0480.111
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0040.005
Scholarly communication0.0130.012
Open science0.0040.015
Research integrity0.0150.012
Insufficient payload (model declined to judge)0.2620.157

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.293
Teacher spread0.274 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same topicInflammatory Bowel Disease→French-language works237,207→